Jeff Bezos, former Amazon CEO, is among the first major investors in Altos Labs—a pioneering startup focused on regenerative medicine and cellular rejuvenation. This ambitious venture draws from decades of Nobel-winning research, positioning Bezos at the forefront of potential breakthroughs in human longevity.
In July 2021, Jeff Bezos stepped down as Amazon CEO but retained his role as executive chairman. Weeks later, Forbes crowned him the world's richest person with $209.2 billion in assets. Beyond Amazon, Bezos founded Blue Origin for aerospace innovation. In 2019, he revealed a visionary plan: transporting 1,000 billion humans in massive orbital ships.
A September 4, 2021, MIT Technology Review article spotlighted Bezos' investment in Altos Labs, founded by Russian billionaire Yuri Milner. The company commits substantial funding to elite researchers tackling cell longevity through regenerative medicine.
Key figures include Nobel laureates Jennifer Doudna and Emmanuelle Charpentier (Chemistry 2020) for CRISPR-Cas9 gene editing, and Shinya Yamanaka (Medicine 2012) for cellular reprogramming—resetting cells to a stem-like state.
These advances hold promise for curing intractable diseases, rejuvenating organs, and potentially the entire body. Originally philanthropic, Altos Labs now pursues commercial goals, planning labs in the US, UK, and Japan.
Altos Labs recruits top talent like Steve Horvath (UC Berkeley), inventor of the epigenetic clock for precise cellular aging measurement; Peter Walter (UC San Francisco), researching Alzheimer's; and Wolf Reik, a reprogramming expert.
Juan Carlos Izpisúa Belmonte (Salk Institute) joins after CRISPR trials slowing progeria in mice and controversial human-ape embryo chimeras.
With competitive salaries, unrestricted research freedom, and state-of-the-art facilities, the team targets full organ regeneration—liver, heart, skin—and ultimately, longevity extension for those who can afford it, like Bezos.
